PranaX Corporation, a pioneer in exosome-based regenerative wellness, has appointed Phillip Maderia as its new Chief Executive Officer.

Maderia boasts over three decades of leadership in biopharmaceutical manufacturing, most notably in pioneering exosome production.

He joins PranaX from Lonza, where he served as Site Head and exosome Business Leader of the Lexington, MA, manufacturing facility since 2021. At Lonza, he spearheaded the expansion of the exosome business, overseeing a $12M operation and leading the construction of Lonza’s first 500L-scale GMP exosome manufacturing process. His strategic vision was instrumental in Lonza’s acquisition of Codiak BioSciences’ intellectual property and clinical programs in 2023, cementing the company’s leadership in the exosome field.

Before Lonza, Maderia served as VP Manufacturing Operations at Codiak BioSciences where he led the supply of three exosome clinical programs in oncology, and at LFB-USA and Sanofi Genzyme, where he held senior roles in manufacturing and engineering leadership in biologics manufacturing.

“I’m thrilled to lead PranaX at this exciting juncture,” said Maderia. “Exosomes represent a frontier in regenerative wellness, and PranaX’s mission to make these benefits widely accessible resonates deeply with me. I look forward to driving our team to deliver natural, science-driven products that empower people to live healthier, more vibrant lives.”

Under Maderia’s leadership, PranaX aims to expand its research pipeline, forge strategic partnerships, and bring its exosome solutions to market.